Evidence map›Paper›PMID 26384674›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2016

Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

W Yao, W Dai, L Jiang, E Y-A Lay, Z Zhong, R O Ritchie, X Li, H Ke, N E Lane

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. mClinical and translational medicine · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. The Role of Sclerostin in Bone Diseases.Journal of clinical medicine · 2022
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

W Yao *Center for Musculoskeletal Health, Internal Medicine, University of California at Davis Medical Center, Sacramento, CA 95817, USA.
W Dai *Center for Musculoskeletal Health, Internal Medicine, University of California at Davis Medical Center, Sacramento, CA 95817, USA.
L JiangCenter for Musculoskeletal Health, Internal Medicine, University of California at Davis Medical Center, Sacramento, CA 95817, USA.
E Y-A LayCenter for Musculoskeletal Health, Internal Medicine, University of California at Davis Medical Center, Sacramento, CA 95817, USA.
Z ZhongCenter for Musculoskeletal Health, Internal Medicine, University of California at Davis Medical Center, Sacramento, CA 95817, USA.
R O RitchieDepartment of Materials Science and Engineering, University of California at Berkeley, Berkeley, CA 94720, USA.
X LiDepartment of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA.
H KeDepartment of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA.
N E LaneCenter for Musculoskeletal Health, Internal Medicine, University of California at Davis Medical Center, Sacramento, CA 95817, USA.
University of California Davis Medical Center · USAmgen (United States) · USLonghua Hospital Shanghai University of Traditional Chinese Medicine · CNUniversity of California, Berkeley · US

Funding

Translation of Quantitative Imaging in OsteoarthritisP50AR060752 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SOUZA, RICHARD BRIAN · 2011 to 2015
$6.2M
Sex Differences in response to an exercise for hyperkyphosisP50AR063043 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KATZMAN, WENDY BETH · 2012 to 2017
$5.7M
3D IN VIVO MORPHOMETRY OF TRABECULAR MICROSTRUCTURER01AR043052 · NIAMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LANE, NANCY E · 1995 to 2014
$5.0M
Directing mesenchymal stem cells to bone to augment bone formationR01AR061366 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YAO, WEI · 2012 to 2015
$1.1M
NIAMS NIH HHS K24 AR04884NIAMS NIH HHS P50 AR060752NIAMS NIH HHS P50 AR063043NIAMS NIH HHS R01 AR043052NIAMS NIH HHS R01 AR061366
6 · The paper itself

Abstract

unlabelledThis study was to determine if antibody against sclerostin (Scl-Ab) could prevent glucocorticoid (GC)-induced osteoporosis in mice. We found that Scl-Ab prevented GC-induced reduction in bone mass and bone strength and that the anabolic effects of Scl-Ab might be partially achieved through the preservation of osteoblast activity through autophagy.

introductionGlucocorticoids (GCs) inhibit bone formation by altering osteoblast and osteocyte cell activity and lifespan. A monoclonal antibody against sclerostin, Scl-Ab, increased bone mass in both preclinical animal and clinical studies in subjects with low bone mass. The objectives of this study were to determine if treatment with the Scl-Ab could prevent loss of bone mass and strength in a mouse model of GC excess and to elucidate if Scl-Ab modulated bone cell activity through autophagy.

methodsWe generated reporter mice that globally expressed dsRed fused to LC3, a protein marker for autophagosomes, and evaluated the dose-dependent effects of GCs (0, 0.8, 2.8, and 4 mg/kg/day) and Scl-Ab on autophagic osteoblasts, bone mass, and bone strength.

resultsGC treatment at 2.8 and 4 mg/kg/day of methylprednisolone significantly lowered trabecular bone volume (Tb-BV/TV) at the lumbar vertebrae and distal femurs, cortical bone mass at the mid-shaft femur (FS), and cortical bone strength compared to placebo (PL). In mice treated with GC and Scl-Ab, Tb-BV/TV increased by 60-125 %, apparent bone strength of the lumbar vertebrae by 30-70 %, FS-BV by 10-18 %, and FS-apparent strength by 13-15 %, as compared to GC vehicle-treated mice. GC treatment at 4 mg/kg/day reduced the number of autophagic osteoblasts by 70 % on the vertebral trabecular bone surface compared to the placebo group (PL, GC 0 mg), and GC + Scl-Ab treatment.

conclusionsTreatment with Scl-Ab prevented GC-induced reduction in both trabecular and cortical bone mass and strength and appeared to maintain osteoblast activity through autophagy.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntibodies, MonoclonalAutophagyBody WeightBone DensityBone RemodelingDisease Models, AnimalDose-Response Relationship, DrugDrug Evaluation, PreclinicalFemurGlucocorticoidsGlycoproteinsIntercellular Signaling Peptides and ProteinsLumbar VertebraeMaleAdaptor Proteins, Signal TransducingAntibodies, MonoclonalGlucocorticoidsGlycoproteinsIntercellular Signaling Peptides and ProteinsSost protein, mouseAutophagydsRed-LC3 mouseGlucocorticoid-induced osteoporosisOsteoblastSclerostin-antibody

Identifiers

PMID26384674
PMCPMC4958115
OpenAlexW1644079882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.